Project Grant R01DA067016
Award Date 8/15/26
Completion Date 6/30/31
Dollars Obligated $509K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded the University of North Carolina at Chapel Hill $908,804 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the effects of acute fentanyl and xylazine exposure on neural respiratory centers. The research examines how acute exposure to ultra-potent synthetic opioids and drug supply adulterants—fentanyl, xylazine, and dexmedetomidine—affect respiration and behavior through adaptations in the...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $423,500 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neuropharmacology of xylazine and fentanyl interactions. The recipient will characterize the pharmacological mechanisms of xylazine alone and in combination with fentanyl using preclinical models of analgesia, sedation, opioid tolerance, opioid withdrawal, and opioid self-administration in mice. The...
- This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...
- The National Institute on Drug Abuse awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $618,725 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate fentanyl overdose-induced anhedonia and relapse risk. The research examines whether fentanyl overdose intensifies addiction cycles through alterations in reward processing. The project tests three specific aims: whether fentanyl overdose leads to development or...
- The National Institutes of Health Office of the Director awarded the University of California, San Diego $480,000 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct research on metabolic-epigenetic mechanisms of neurotoxicity following acute fentanyl exposure. The project, which runs through June 30, 2031, investigates how ultra-potent synthetic opioids such as fentanyl cause delayed neurological consequences in overdose survivors despite effective opioid...
- The National Institutes of Health Office of the Director awarded University of Massachusetts Medical School $479,385 on June 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate targeting platelet-derived growth factor receptor beta (PDGFR-beta) as a means to prevent opioid-induced respiratory depression and overdose deaths. The research combines behavioral pharmacology and neuroanatomical protein and mRNA expression mapping in the mouse brainstem to test the...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $434,005 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate xylazine's mechanisms of action on human cell receptors and identify natural product compounds that can reverse xylazine-induced damage. The research addresses a critical gap in understanding xylazine's pharmacological effects beyond its known action on alpha-2 adrenergic receptors. Current FDA-approved medications,...
- The National Institutes of Health Office of the Director awarded the University of Miami a project grant of $460,500 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate microbiome-mediated persistent neuroimmune injury following single fentanyl exposure. The research examines how ultra-potent synthetic opioids such as fentanyl induce delayed biological injury in survivors of sub-lethal exposure, with focus on mechanisms underlying impaired cognition...
- The National Institute on Drug Abuse awarded The Leland Stanford Junior University $158,534 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate opioid-induced dopamine rhythms and their role in respiratory suppression. The research investigates rhythmic dopamine release that occurs after repeated high-dose fentanyl exposure and may underlie agonal breathing responses in opioid overdose. Preliminary data demonstrate that opioid-induced rhythmic...